Anandamide inhibits Theiler's virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB1 receptors

Journal of Neuroinflammation

Volumn 8, Issue , 2011, Pages

  Mestre, Leyre ^a   Iñigo, Paula M ^a   Mecha, Miriam ^a   Correa, Fernando G ^a,b   Hernangómez Herrero, Miriam ^a   Loría, Frida ^a   Docagne, Fabian ^a,c   Borrell, José ^a   Guaza, Carmen ^a  

^a INSTITUTO CAJAL   (Spain)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c GIP CYCERON   (France)

Author keywords

Blood brain barrier; Endocannabinoids; Multiple Sclerosis; TMEV; VCAM 1

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CAPSAZEPINE; N (3 FURYLMETHYL)ARACHIDONAMIDE; RIMONABANT; VASCULAR CELL ADHESION MOLECULE 1; AMIDE; ARACHIDONIC ACID DERIVATIVE; ENDOCANNABINOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN CELL; COCULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENE FUNCTION; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE MIGRATION INHIBITION; MICROGLIA; MORNING DOSAGE; MOUSE; MULTIPLE SCLEROSIS; MURINE ENCEPHALOMYELITIS VIRUS; NONHUMAN; VIRUS INDUCTION; VIRUS INFECTION; VIRUS INHIBITION; WILD TYPE; ANIMAL; BRAIN; CELL ADHESION; CYTOLOGY; DRUG EFFECT; FEMALE; GENETICS; HUMAN; LEUKOCYTE; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

ANIMALS; ARACHIDONIC ACIDS; BLOOD-BRAIN BARRIER; BRAIN; CELL ADHESION; ENDOCANNABINOIDS; ENDOTHELIAL CELLS; FEMALE; HUMANS; LEUKOCYTES; MICE; MICE, KNOCKOUT; MICROGLIA; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB1; THEILOVIRUS; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 80051802511     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-8-102     Document Type: Article

References (64)

1. Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 2005, 26:485-495. 10.1016/j.it.2005.07.004, 16039904.
2. Greenwood J, Heasman SJ, Alvarez JI, Prat A, Lyck R, Engelhardt B. Leucocyte-endothelial cell crosstalk at the blood-brain barrier: A prerequisite for successful immune cell entry to the brain. Neuropathol Appl Neurobiol 2011, 37:24-39. 10.1111/j.1365-2990.2010.01140.x, 20946472.
3. Ukkonen M, Wu K, Reipert B, Dastidar P, Elovaara I. Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis. Mult Scler 2007, 13:701-707. 10.1177/1352458506075378, 17613596.
4. Brosnan CF, Cannella B, Battistini L, Raine CS. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 1995, 45:S16-S21.
5. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992, 356:63-66. 10.1038/356063a0, 1538783.
6. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, . AFFIRM Investigators A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910. 10.1056/NEJMoa044397, 16510744, AFFIRM Investigators.
7. Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, Hoelzl M, Künz B, Lutterotti A, Rudzki D, Berger T, Reindl M, Deisenhammer. Natalizumab treatment reduces endothelial activity in MS patients. J Neuroimmunol 2010, 227:190-194. 10.1016/j.jneuroim.2010.07.012, 20739072.
8. Lipton HL, Dal Canto MC. Chronic neurologic disease in Theiler's virus infection of SJL/J mice. J Neurol Sci 1976, 30:201-207. 10.1016/0022-510X(76)90267-7, 978224.
9. Maccarrone M, Dainese E, Oddi S. Intracellular trafficking of anandamide: new concepts for signaling. Trends Biochem Sci 2010, 35:601-608. 10.1016/j.tibs.2010.05.008, 20570522.
10. Scotter EL, Abood ME, Glass M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol 2010, 160:480-498. 10.1111/j.1476-5381.2010.00735.x, 2931550, 20590559.
11. Rossi S, Bernardi G, Centonze D. The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Exp Neurol 2010, 224:92-102. 10.1016/j.expneurol.2010.03.030, 20353778.
12. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutiérrez SO, van der Stelt M, López-Rodriguez ML, Casanova E, Schütz G, Zieglgänsberger W, Di Marzo V, Behl C, Lutz B. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003, 302:84-88. 10.1126/science.1088208, 14526074.
13. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, Hoertnagl H, Raine CS, Schneider-Stock R, Nitsch R, Ullrich O. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006, 49:67-79. 10.1016/j.neuron.2005.11.027, 16387640.
14. Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, Shohami E. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 2006, 22:257-264. 10.1016/j.nbd.2005.11.004, 16364651.
15. Centonze D, Bari M, Rossi S, Prosperetti C, Furlan R, Fezza F, De Chiara V, Battistini L, Bernardi G, Bernardini S, Martino G, Maccarrone M. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 2007, 130:2543-2553. 10.1093/brain/awm160, 17626034.
16. Fowler CJ, Rojo ML, Rodriguez-Gaztelumendi A. Modulation of the endocannabinoid system: neuroprotection or neurotoxicity?. Exp Neurol 2010, 224:37-47. 10.1016/j.expneurol.2010.03.021, 20353772.
17. Cabranes A, Venderova K, de Lago E, Fezza F, Sánchez A, Mestre L, Valenti M, García-Merino A, Ramos JA, Di Marzo V, Fernández-Ruiz J. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol Dis 2005, 20:207-217. 10.1016/j.nbd.2005.03.002, 16242629.
18. Ortega-Gutiérrez S, Molina-Holgado E, Arévalo-Martín A, Correa F, Viso A, López-Rodríguez ML, Di Marzo V, Guaza C. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J 2005, 19:1338-1340.
19. Centonze D, Battistini L, Maccarrone M. The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. Curr Pharm Des 2008, 14:2370-2342. 10.2174/138161208785740018, 18781987.
20. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo V. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001, 15:300-302.
21. Arévalo-Martín A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 2003, 23:2511-2516.
22. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A, . UK MS Research Group Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003, 362:1517-1526. 10.1016/S0140-6736(03)14738-1, 14615106, UK MS Research Group.
23. Ni X, Geller EB, Eppihimer MJ, Eisenstein TK, Adler MW, Tuma RF. Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler 2004, 10:158-164. 10.1191/1352458504ms1009oa, 15124761.
24. Mestre L, Docagne F, Correa F, Loría F, Hernangómez M, Borrell J, Guaza C. A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol Cell Neurosci 2009, 40:258-266. 10.1016/j.mcn.2008.10.015, 19059482.
25. Lledó A, Borrell J, Guaza C. Dexamethasone regulation of interleukin-1-receptors in the hippocampus of Theiler's virus-infected mice: effects on virus-mediated demyelination. Eur J Pharmacol 1999, 372:75-83. 10.1016/S0014-2999(99)00187-9, 10374717.
26. Laschinger M, Engelhardt B. Interaction of alpha4-integrin with VCAM-1 is involved in adhesion of encephalitogenic T cell blasts to brain endothelium but not in their transendothelial migration in vitro. J Neuroimmunol 2000, 102:32-43. 10.1016/S0165-5728(99)00156-3, 10626664.
27. Omidi Y, Campbell L, Barar J, Connell D, Akhtar S, Gumbleton M. Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, as an in vitro blood-brain barrier model for drug uptake and transport studies. Brain Res 2003, 990:95-112. 10.1016/S0006-8993(03)03443-7, 14568334.
28. Yang T, Roder KE, Abbruscato TJ. Evaluation of bEnd5 cell line as an in vitro model for the blood-brain barrier under normal and hypoxic/aglycemic conditions. J Pharm Sci 2007, 96:3196-3213. 10.1002/jps.21002, 17828743.
29. Molina-Holgado F, Lledó A, Guaza C. Evidence for cyclooxygenase activation by nitric oxide in astrocytes. Glia 1995, 15:167-172. 10.1002/glia.440150209, 8567068.
30. Gaillard PJ, Voorwinden LH, Nielsen JL, Ivanov A, Atsumi R, Engman H, Ringbom C, de Boer AG, Breimer DD. Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur J Pharm Sci 2001, 12:215-222. 10.1016/S0928-0987(00)00123-8, 11113640.
31. Eugenin EA, Berman JW. Chemokine-dependent mechanisms of leukocyte trafficking across a model of the blood-brain barrier. Methods 2003, 29:351-361. 10.1016/S1046-2023(02)00359-6, 12725802.
32. Golech SA, McCarron RM, Chen Y, Bembry J, Lenz F, Mechoulam R, Shohami E, Spatz M. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res 2004, 132:87-92.
33. O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 2007, 152:576-582. 2190029, 17704824.
34. Wolf SA, Tauber S, Ullrich O. CNS immune surveillance and neuroinflammation: endocannabinoids keep control. Curr Pharm Des 2008, 14:2266-2278. 10.2174/138161208785740090, 18781977.
35. Molina-Holgado E, Molina-Holgado F. Mending the broken brain: neuroimmune interactions in neurogenesis. J Neurochem 2010, 114:1277-1290.
36. Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009, 156:397-411. 10.1111/j.1476-5381.2008.00048.x, 2697681, 19226257.
37. Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertwee RG, Yamamura T, Baker D. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J Neuroimmunol 2008, 193:120-129. 10.1016/j.jneuroim.2007.10.024, 18037503.
38. Sapatino BV, Petrescu AD, Rosenbaum BA, Smith R, Piedrahita JA, Welsh CJ. Characteristics of cloned cerebrovascular endothelial cells following infection with Theiler's virus. II. Persistent infection. J Neuroimmunol 1995, 62:127-135. 10.1016/0165-5728(95)00094-4, 7499500.
39. Inoue A, Koh CS, Yamazaki M, Ichikawa M, Isobe M, Ishihara Y, Yagita H, Kim BS. Anti-adhesion molecule therapy in Theiler's murine encephalomyelitis virus-induced demyelinating disease. Int Immunol 1997, 9:1837-1847. 10.1093/intimm/9.12.1837, 9466311.
40. Mestre L, Correa F, Docagne F, Clemente D, Guaza C. The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. Biochem Pharmacol 2006, 72:869-880. 10.1016/j.bcp.2006.06.037, 16914119.
41. Maccarrone M, Fiori A, Bari M, Granata F, Gasperi V, De Stefano ME, Finazzi-Agrò A, Strom R. Regulation by cannabinoid receptors of anandamide transport across the blood-brain barrier and through other endothelial cells. Thromb Haemost 2006, 95:117-127.
42. Lu TS, Avraham HK, Seng S, Tachado SD, Koziel H, Makriyannis A, Avraham S. Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells. J Immunol 2008, 181:6406-6416.
43. Zhang H, Hilton DA, Hanemann CO, Zajicek J. Cannabinoid Receptor and N-acyl Phosphatidylethanolamine Phospholipase D-Evidence for Altered Expression in Multiple Sclerosis. Brain Pathol 2011,
44. Benito C, Romero JP, Tolón RM, Clemente D, Docagne F, Hillard CJ, Guaza C, Romero J. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 2007, 27:2396-402. 10.1523/JNEUROSCI.4814-06.2007, 17329437.
45. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, Banati RR, Anand P. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 2006, 6:12. 10.1186/1471-2377-6-12, 1413551, 16512913.
46. Ramirez SH, Heilman D, Morsey B, Potula R, Haorah J, Persidsky Y. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses Rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV-1 infected monocytes. J Immunol 2008, 180:1854-1865.
47. Craig LE, Spelman JP, Strandberg JD, Zink MC. Endothelial cells from diverse tissues exhibit differences in growth and morphology. Microvasc Res 1998, 55:65-76. 10.1006/mvre.1997.2045, 9473410.
48. Chen P, Hu S, Yao J, Moore SA, Spector AA, Fang X. Induction of cyclooxygenase-2 by anandamide in cerebral microvascular endothelium. Microvasc Res 2005, 69:28-35. 10.1016/j.mvr.2005.02.001, 15797258.
49. Loría F, Petrosino S, Mestre L, Spagnolo A, Correa F, Hernangómez M, Guaza C, Di Marzo V, Docagne F. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci 2008, 28:633-641. 10.1111/j.1460-9568.2008.06377.x, 18657182.
50. Mestre L, Correa F, Arévalo-Martín A, Molina-Holgado E, Valenti M, Ortar G, Di Marzo V, Guaza C. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem 2005, 92:1327-1339. 10.1111/j.1471-4159.2004.02979.x, 15748152.
51. Wagner JA, Hu K, Karcher J, Bauersachs J, Schäfer A, Laser M, Han H, Ertl G. CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. Br J Pharmacol 2003, 138:1251-1258. 10.1038/sj.bjp.0705156, 1573770, 12711625.
52. Battista N, Fezza F, Maccarrone M. Endocannabinoids and their involvement in the neurovascular system. Curr Neurovasc Res 2004, 1:129-140. 10.2174/1567202043480107, 16185189.
53. Walter L, Stella N. Endothelin-1 increases 2-arachidonoyl glycerol (2-AG) production in astrocytes. Glia 2003, 44:85-90. 10.1002/glia.10270, 12951660.
54. Stella N. Endocannabinoid signaling in microglial cells. Neuropharmacology 2009, 56:244-253. 2654419, 18722389.
55. Mechoulam R, Shohami E. Endocannabinoids and traumatic brain injury. Mol Neurobiol 2007, 36:68-74. 10.1007/s12035-007-8008-6, 17952651.
56. Ullrich O, Merker K, Timm J, Tauber S. Immune control by endocannabinoids - new mechanisms of neuroprotection?. J Neuroimmunol 2007, 184:127-135. 10.1016/j.jneuroim.2006.11.018, 17196262.
57. Olson JK, Miller SD. The innate immune response affects the development of the autoimmune response in Theiler's virus-induced demyelinating disease. J Immunol 2009, 182:5712-5722. 10.4049/jimmunol.0801940, 2876715, 19380818.
58. Molina-Holgado F, Molina-Holgado E, Guaza C. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett 1998, 433:139-142. 10.1016/S0014-5793(98)00851-5, 9738948.
59. Correa F, Hernangómez-Herrero M, Mestre L, Loría F, Docagne F, Guaza C. The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: Evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. Brain Behav Immun 2011, 25:736-749. 10.1016/j.bbi.2011.01.020, 21310228.
60. Jin YH, Mohindru M, Kang MH, Fuller AC, Kang B, Gallo D, Kim BS. Differential virus replication, cytokine production, and antigen-presenting function by microglia from susceptible and resistant mice infected with Theiler's virus. J Virol 2007, 81:11690-11702. 10.1128/JVI.01034-07, 2168808, 17715222.
61. Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cuzner ML, Baker D. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003, 126:2191-2202. 10.1093/brain/awg224, 12876144.
62. Jackson SJ, Pryce G, Diemel LT, Cuzner ML, Baker D. Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience 2005, 134:, 261-268.
63. Ramil E, Sánchez AJ, González-Pérez P, Rodríguez-Antigüedad A, Gómez-Lozano N, Ortiz P, Arroyo R, De las Heras V, Vilches C, García-Merino A. The cannabinoid receptor 1 gene (CNR1) and multiple sclerosis: an association study in two case-control groups from Spain. Mult Scler 2010, 16:139-146. 10.1177/1352458509355071, 20007426.
64. Rossi S, Buttari F, Studer V, Motta C, Gravina P, Castelli M, Mantovani V, De Chiara V, Musella A, Fiore S, Masini S, Bernardi G, Maccarrone M, Bernardini S, Centonze D. The (AAT)n repeat of the cannabinoid CB1 receptor gene influences disease progression in relapsing multiple sclerosis. Mult Scler 2011, 7:281-288.